The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.
Johnson & Johnson removed two risks related to its Consumer Health separation, reflecting the completion or abandonment of that strategic initiative, while adding a new risk regarding complex governmental regulations across operating countries. Twelve of the company's existing risk disclosures were substantively modified, with notable updates to liquidity and credit rating risks, international operations exposure, and competitive market pressures, suggesting J&J refined its risk characterization in response to evolving market conditions and regulatory environments.
Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🟢 New in Current Filing
We are subject to an increasing number of costly and complex governmental regulations in the countries in which operations are conducted which may materially adversely affect the Company’s financial condition and business operations.
🔒
🔴 No Match in Current Filing
The planned separation of the Company’s Consumer Health business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results.
🔒
🔴 No Match in Current Filing
Following the planned separation, the price of shares of the Company’s common stock may fluctuate significantly.
🔒
🟡 Modified
Weak financial performance, failure to maintain a satisfactory credit rating or disruptions in the financial markets could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.
🔒
🟡 Modified
The Company faces a variety of financial, economic, legal, social and political risks associated with conducting business internationally.
🔒
🟡 Modified
The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
🔒
🟡 Modified
Significant challenges or delays in the Company’s innovation, development and implementation of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
🔒
🟡 Modified
The Company relies on third parties to manufacture and supply certain of our products. Any failure by or loss of a third-party manufacturer or supplier could result in delays and increased costs, which may adversely affect our business.
🔒
🟡 Modified
Global sales in the Company’s Innovative Medicine and MedTech segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
🔒
🟡 Modified
The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
🔒
🟡 Modified
An information security incident, including a cybersecurity breach, could have a negative impact on the Company’s business or reputation.
🔒
🟡 Modified
Global health crises, pandemics, epidemics, or other outbreaks could adversely disrupt or impact certain aspects of the Company’s business, results of operations and financial condition.
🔒
🟡 Modified
The Separation could result in substantial tax liability.
🔒
🟡 Modified
Due to the international nature of the Company's business, geopolitical or economic changes or events, including global tensions and war, could adversely affect our business, results of operations or financial condition.
🔒
🟡 Modified
The Company may be unable to achieve some or all of the anticipated strategic and financial benefits following the separation of Kenvue Inc. (Kenvue), including with respect to the Company’s remaining ownership interest.
🔒